Market Overview

Merck Earnings: The Street And The Crowd Expect A Double-Digit Year-Over-Year Decline

Share:

Merck & Co., Inc. (NYSE: MRK) is scheduled to report its first quarter financial results before the market opens on Tuesday.

According to Estimize, Wall Street analysts project consensus EPS of $0.75 on revenue of $8.98 billion. This implies a decline of more than 14 percent from the earnings of $0.88 per share reported in the same quarter last year, and a 13.7 percent decay from last quarter’s $0.87.

The crowd is a little bit less bearish, and expects EPS of $0.78 on revenue of $9.105 billion.

The company did not provide guidance for the quarter.

Related Link: Morgan Stanley Awaits This Merck Data

The graph below shows Merck’s history of estimates versus actual earnings:

Estimates have also been falling over the quarter.

While Wall Street has been losing confidence in Merck over the quarter, the crowd’s expectations have been pretty much flat. However, they both expect the company to report a decline in earnings, both year-over-year and quarter-over-quarter.

What Analysts Think

In a recently published report, Morgan Stanley provided a preview of major pharmaceutical companies’ first quarter results and listed key events for the second quarter.

The firm expects EPS of $0.73 for the first quarter, even lower than consensus estimates. Key events for Q2 include the “FDA panel action on DPP-IVs on Tuesday April 14 and Januvia TECOS CV outcomes trial result details in June at ADA, 2) Keytruda (immuno-oncology) trial results at AACR in Philadelphia April 19-20 and ASCO May 29 - June 3.”

Posted-In: Estimize Morgan StanleyAnalyst Color Biotech Health Care Previews Trading Ideas General

 

Related Articles (MRK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
PEPMacquarieMaintains138.0
POLBuckinghamMaintains36.0
BKBuckinghamMaintains53.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Can GoPro Repeat Q4 Success In Q1?

Why Is ESPN Suing Verizon?